New large-capacity bioprocessing centrifuge enhances productivity and reliability
Thermo Scientific Sorvall BIOS 16 centrifuge is designed to provide simplified, flexible bioprocessing.
Thermo Scientific Sorvall BIOS 16 centrifuge designed to provide simplified, flexible bioprocessing.
Designed to maximize productivity for bioprocessing customers, the new Thermo Scientific Sorvall BIOS 16 centrifuge offers an increased capacity of up to 16 liters of cell culture product per run and unique design features to make working with large volumes easier and more convenient.
In the increasingly complex, regulated and fast-paced bioprocessing environment, users require a centrifuge with simple operation and high-throughput capabilities that deliver run-to-run reproducibility while maintaining sample integrity. These elements are essential to manufacturing products in a scalable, consistent and safe manner. In the development and manufacturing of biological products, centrifuges that support separation and purification processes are typically larger and are used continuously. Therefore, users put a high priority on ergonomically designed platforms.
The Thermo Scientific Sorvall BIOS 16 centrifuge includes several features designed to enhance the user experience, including
“For more than 60 years, Thermo Fisher Scientific has demonstrated application expertise across its centrifuge systems, and the addition of the Sorvall BIOS 16 bioprocessing centrifuge builds upon that commitment to delivering innovative designs to meet specific user needs,” said Monica Manotas, vice president and general manager, growth, protection and separation products at Thermo Fisher Scientific. “Now, bioprocessing centers around the world can reap the benefits of this unique, user-friendly system designed to provide high-throughput sample processing, simple, quick set-up and remote monitoring, energy savings, compliance with global safety standards and enhanced ergonomics with every run.”
The new Sorvall BIOS 16 bioprocessing centrifuge offers the flexibility to select higher-capacity rotors or match existing workflows, with a choice of four swinging bucket rotors ranging from 6 x 1000 mL to 8 x 2000 mL. This product is listed with the FDA and complies with the latest global safety standards including UL and CE.
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...